|
Shionogi & Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sales of prescription medicines. The company operates as a single business segment and focuses on therapeutic areas including infectious diseases, pain treatment, and metabolic diseases. Key products include the antibiotic Shiomarin, the hyperlipidemia treatment Crestor, and the anti-HIV agent Tivicay. The group structure includes subsidiaries such as Shionogi Pharma, Shionogi Healthcare, Shionogi Inc., Qpex Biopharma, Tetra Therapeutics, and ViiV Healthcare. Shionogi was founded in 1878 as a drug wholesaler and has since evolved into a manufacturer of proprietary antibiotics and other pharmaceuticals. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage shionogi.com |
| Sector Healthcare | IR page shionogi.com/global/en/investors.html | |
|
Tags
antibiotics, anti-hiv, hyperlipidemia, pain treatment, infectious diseases, metabolic diseases, prescription medicines, Shionogi Pharma, Shionogi Healthcare, Shionogi Techno Advance Research, Torii Pharmaceutical, Shionogi Business Partner, Shionogi Inc., Qpex Biopharma, Tetra Therapeutics, Shionogi-Apnimed Sleep Science, Shionogi B.V., ViiV Healthcare, Shinomin, Shiomarin, Crestor, Tivicay
|
Press page shionogi.com/global/en/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 2.525T |
| Market cap (USD) | $ 15.852B |
| P/E | 10.02 |
| PEG | 2.85 |
| P/BV | 1.45 |
| P/S | 5.05 |
| P/OCF | 11.82 |
| P/FCF | 12.68 |
| Dividend yield | 2.5% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 13.5% |
| ROI | 12.2% |
| ROIC | 8.5% |
| Profit margin | 41.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 3.5% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 39 |
| Quality score | 33.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 499.677B | 438.268B | 410.073B | 426.684B | 335.138B | 297.177B | 333.371B | 363.721B | 344.667B | 338.89B | 309.973B | 273.991B | 289.717B | 282.903B |
| Net profit | 205.159B | 170.435B | 162.03B | 184.965B | 114.185B | 111.858B | 122.193B | 132.759B | 108.866B | 83.879B | 66.687B | 44.06B | 40.618B | 66.727B |
| Free cash flow | 199.108B | 143.357B | 126.017B | 140.68B | 70.504B | 80.857B | 120.172B | 136.56B | 112.778B | 88.644B | 87.19B | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 3.472K | 2.244K | 7.767K | 5.976K | 7.526K | 5.952K | 5.307K | 6.852K | 5.491K | 5.748K | 5.301K | 4.005K | 1.913K | 1.943K |
| Price performance 12m | 0.55 | -0.71 | 0.3 | -0.21 | 0.26 | 0.12 | -0.23 | 0.25 | -0.04 | 0.08 | 0.32 | 1.09 | -0.02 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 59.3B | 53.2B | 101B | 79.8B | 78B | 123B | 110B | 123B | 121B | 160B |
| ↳ YoY growth | -9.0% | -10.3% | -20.9% | -2.2% | +57.6% | -10.7% | +11.9% | -1.9% | +32.5% | |
| ↳ 5y CAGR | +4.0% | +8.6% | +15.4% | |||||||
| Borrowings, current (JPY) | — | 10B | 918M | — | — | — | — | — | — | 660B |
| Borrowings, non-current (JPY) | 30.1B | 18.5B | — | — | — | — | — | — | — | — |
| Bonds payable (JPY) | 20.1B | 18.5B | 920M | — | — | — | — | — | — | — |
| Lease liabilities (JPY) | — | — | 9.31B | 8.15B | 7.99B | 6.67B | 9.41B | 11.6B | 21.9B | 24.4B |
| Cash and deposits (JPY) | 108B | 140B | 196B | 209B | 276B | 254B | 309B | 358B | 375B | 711B |
| Intangible assets (JPY) | 91.1B | 75.1B | 47.8B | 46.5B | 76.6B | 81.2B | 96.3B | 118B | 144B | 174B |
| Right-of-use assets (JPY) | — | — | 5.92B | 4.66B | 4.83B | 3.52B | 6.48B | 9.44B | 19.4B | 22.8B |
| Net debt (borrowings + leases - cash) (JPY) | -77.8B | -112B | -186B | — | — | — | — | — | — | -27B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 112B | 130B | 165B | 132B | 109B | 102B | 178B | 154B | 195B | 214B |
| Purchases of property, plant and equipment (JPY) | -10.4B | -5.88B | -6.55B | -8.95B | -28.2B | -26.2B | -11.9B | -12.7B | -17.1B | -14.5B |
| Purchases of intangible assets (JPY) | -12.8B | -11.1B | -18.8B | -2.82B | -4.76B | -5.38B | -25.3B | -15.6B | -35B | -16.8B |
| Change in receivables (cash effect) (JPY) | 5.8B | 5.97B | -18.6B | 21.4B | 2.99B | -43.4B | 13.9B | -12.4B | 1.91B | -2.58B |
| Change in inventories (cash effect) (JPY) | 625M | 6.55B | -3.64B | 1.16B | -3.44B | -7.13B | -11.7B | -6.34B | -388M | -12.7B |
| Change in payables (cash effect) (JPY) | 893M | -3.81B | 4.92B | -5.75B | -2.38B | 11.7B | 7.74B | -5.82B | -1.7B | 7.03B |
| Dividends paid (cash effect) (JPY) | -22.1B | -24.2B | -27.6B | -31.1B | -32.5B | -33.1B | -36.1B | -43.9B | -48.7B | -56.2B |
| Share buybacks (cash effect) (JPY) | -35B | -29.4B | -50.3B | -50.2B | -50.1B | -14M | -49.5B | -75.2B | -10M | -5M |
| Interest paid (cash effect) (JPY) | -207M | -545M | -693M | -348M | -256M | -87M | -94M | -164M | -305M | -344M |
| Income taxes paid (cash effect) (JPY) | -34B | -38.6B | -23.7B | — | — | -39.3B | -27.3B | — | — | — |
| Operating cash flow before change in receivables (JPY) | 106B | 124B | 184B | 111B | 106B | 145B | 164B | 167B | 194B | 216B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 88.6B | 113B | 140B | 120B | 76.1B | 70.5B | 141B | 126B | 143B | 182B |
| Income detail | ||||||||||
| Research and development expense (JPY) | 59.9B | 59.9B | 52.1B | 47.9B | 54.2B | 73B | 102B | 103B | 109B | 123B |
| ↳ 5y CAGR | +14.5% | +17.8% | +17.8% | |||||||
| Total comprehensive income (JPY) | 69.4B | 131B | 137B | 36.4B | 138B | 162B | 209B | 254B | 171B | 380B |
| Comprehensive income to owners (JPY) | 70B | 131B | 138B | 36.6B | 137B | 162B | 209B | 255B | 171B | 379B |
| Reported | Jun 22, 2017 | Jun 20, 2018 | Jun 24, 2020 | Jun 24, 2020 | Jun 23, 2021 | Jun 22, 2023 | Jun 22, 2023 | Jun 21, 2024 | Jun 19, 2025 | Jun 19, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Jul 10, 2025 | Acquired | Acquired Torii Pharmaceutical Co., Ltd. (EDINET code E00934). Its filings from before the deal are on its own company page, not shown here. |
ETFs Holding Shionogi & Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| JPAN | 1.12% | 6,500 | $ 111.543K | Jun 30, 2026 |
| RFDI | 0.37% | 33,400 | $ 610.565K | Jul 31, 2026 |
| AVIV | 0.25% | 258,600 | $ 5.166M | Nov 16, 2026 |
| JHID | 0.24% | 1,540 | $ 26.427K | Jun 30, 2026 |
| AVSD | 0.11% | 21,000 | $ 419.521K | Nov 16, 2026 |
| JSTC | 0.09% | 13,320 | $ 270.281K | Nov 17, 2026 |
| DFIV | 0.08% | 864,000 | $ 16.956M | Nov 12, 2026 |
| DFAI | 0.07% | 629,700 | $ 12.358M | Nov 12, 2026 |
| DFIC | 0.05% | 379,300 | $ 7.444M | Nov 12, 2026 |
| AVDE | 0.04% | 356,700 | $ 7.126M | Nov 16, 2026 |
| DXIV | 0.04% | 4,800 | $ 94.199K | Nov 12, 2026 |
| DFSI | 0.04% | 21,400 | $ 419.97K | Nov 12, 2026 |
| DFAX | 0.02% | 148,600 | $ 2.916M | Nov 12, 2026 |
